

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Boill Healthcare Holdings Limited

保集健康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1246)

**(1) CLARIFICATION IN RELATION TO
THE ALLEGED CHANGE OF DIRECTORS AND
COMPOSITION OF BOARD COMMITTEES;
(2) REMOVAL OF COMPANY SECRETARY AND
CHANGE OF AUTHORISED REPRESENTATIVE AND
PROCESS AGENT; AND**

(3) CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

This announcement is made by Boill Healthcare Holdings Limited (the “**Company**”) pursuant to Rules 13.09(2)(a) and 13.51(5) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

CLARIFICATION

Reference is made to the announcements of the Company dated 22 July 2024 regarding the alleged change of directors of the Company and the relevant updated list of directors and their roles and functions (collectively, the “**Announcements**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to clarify that:

- (a) none of (i) the alleged resignations of each of Mr. Zhang Sheng Hai, Mr. Wang Zhe and Mr. Yi Baxian as a Director and the chairman and/or a member of the audit committee, nomination committee and/or remuneration committee of the Company (collectively, the “**Board Committees**”) (as the case may be) and (ii) the alleged appointments of each of Mr. He Yu, Ms. Mak Suet Man, Mr. Chan Chi Hang and Mr. Liang Yanan as a Director and the chairman and/or a member of the Board Committees (as the case may be) as set out in the Announcements (collectively, the “**Alleged Change of Directors**”) had been reviewed or approved by the Board or the nomination committee of the Company;

- (b) the Announcements were released by the then company secretary of the Company without the Board’s proper authorisation. The Company reserves its rights to take appropriate legal actions against the then company secretary. Shareholders and investors of the Company should refer to the information in this announcement and the list of directors and the roles and functions published by the Company on 8 March 2024 instead; and
- (c) there had been no change to the members of the Board or the composition of the Board Committees since 8 March 2024 up to (and including) the date of this announcement; and as at the date of this announcement, the Board consists of six members, namely (i) Mr. Qiu Dongfang and Mr. Zhang Sheng Hai, each an executive Director; (ii) Mr. Chui Kwong Kau, being a non-executive Director; and (iii) Ms. Tang Man Yi, Mr. Yi Baxian and Mr. Wang Zhe, each an independent non-executive Director.

REMOVAL OF COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE AND PROCESS AGENT

The Board announces that Mr. Yuen Wai Keung (“**Mr. Yuen**”) was removed from the position of the company secretary of the Company (the “**Company Secretary**”) as determined by the Board with effect from 23 July 2024.

Mr. Yuen also ceased to act as (i) an authorised representative of the Company (the “**Authorised Representative**”) as required under Rule 3.05 of the Listing Rules and (ii) the process agent of the Company (the “**Process Agent**”) for the acceptance of service of process and notices on behalf of the Company in Hong Kong under Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), both with effect from 23 July 2024.

The Board announces that Mr. Zhang Sheng Hai, being an executive Director, has been appointed as the Authorised Representative and the Process Agent with effect from 23 July 2024.

The Company will use its best endeavours to identify and appoint a suitable candidate as the Company Secretary and make further announcement as and when appropriate.

CHANGE OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The Board further announces that with effect from 23 July 2024, the principal place of business of the Company in Hong Kong has been changed to Unit E, 43/F, Enterprise Square Three, No. 39 Wang Chiu Road, Kowloon Bay, Kowloon, Hong Kong.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Boill Healthcare Holdings Limited
Qiu Dongfang
Executive Director and Chairman

Hong Kong, 24 July 2024

As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Qiu Dongfang and Mr. Zhang Sheng Hai; (ii) one non-executive Director, namely Mr. Chui Kwong Kau; and (iii) three independent non-executive Directors, namely Ms. Tang Man Yi, Mr. Yi Baxian and Mr. Wang Zhe.